Ann: Capital Raising and Strategic Stake Expands Growth Strategy, page-68

First 68 Last

Share
Profile

Follow
Theabyss

1,819 Posts.

93

05/07/21

10:20

Post #: 54279659
Share

Originally posted by Tradingasx ↑

correct I worded what I was thinking differently, rushed the comment rather than checking over it before I sent it.

I still don’t believe a 4.1% discount is going to be relevant in the scheme of things specially with the amount the CR has been achieved along with the revenue, Ebit and dividend component of the RKN business- this is already covered comfortably.

In an open market setting, being a low liquidity & low volatile company on the market, they wouldn’t have been able to access this amount of stock without the pricing jumping over the $1 mark, would have created a hype and frenzie.

by the looks of things RKN may not have direct sold to NOV anyway.

Utilising the big firms and the time it took to raise this with little to no issues indicates and will unlock multiple potential large scale investors & will further bring attention to the Novatti Business.

I know I’ve written this here before but I’ll say it again anyway.
I literally am still surprised that Novatti have a $156M MC considering the significance of their announcements & the relationships they have already formed.

I only now believe the market is starting to wake up to NOV as their SP is definitely underpriced & the next 2 years will see a flock of new investors which will drive the company to ATH.
the growth potential with Novatti is incredible and has the potential to be achieved with relevant ease.

Expand

Agree. Also, now that institutions have sold stakes to Nov, the longer term support for RKN should diminish allowing Nov to buy on market and from institutions to complete the takeover.

NOV Price at posting: 58.5¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 31 more messages in this thread...

First 68 Last

Add NOV (ASX) to my watchlist

(20min delay)
Last 6.5¢		Change -0.006(8.45%)		Mkt cap ! $23.12M

Open	High	Low	Value	Volume
6.6¢	6.7¢	6.4¢	$23.22K	361.4K

Buyers (Bids)

No.	Vol.	Price($)
1	48465	6.2¢

Sellers (Offers)

Price($)	Vol.	No.
6.9¢	100000	1

View Market Depth

No.	Vol.	Price($)
1	48465	0.062
1	40000	0.060
2	189303	0.056
3	90000	0.055
1	180000	0.054

Price($)	Vol.	No.
0.069	100000	1
0.070	50000	1
0.079	38710	1
0.080	235399	3
0.081	1850	1

Last trade - 15.59pm 07/10/2024 (20 minute delay)

NOV (ASX) Chart

Ann: Capital Raising and Strategic Stake Expands Growth Strategy, page-68

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Capital Raising and Strategic Stake Expands Growth Strategy, page-68

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News